Table 2.
iNKT cells used in clinical studies on oncological patients.
| References | Trial ID | Tumor type | n | Treatment |
|---|---|---|---|---|
| Giaccone et al. (113) | – | Solid tumors | 24 | αGalCer |
| Nieda et al. (114) | – | Metastatic solid tumors | 12 | αGalCer/immature MoDC |
| Nicol et al. (115) | – | Metastatic solid tumors | 12 | αGalCer/immature MoDC |
| Chang et al. (116) | – | Advanced cancer | 5 | αGalCer/mature MoDC |
| Ishikawa et al. (117) | UMIN000007321 | NSCLC | 11 | αGalCer/immature DC enriched PBMC |
| Motohashi et al. (118) | – | NSCLC | 6 | αGalCer/IL-2-expanded PBMC |
| Uchida et al. (119) | – | Head and neck SCC | 9 | αGalCer /immature DC-enriched PBMC |
| Motohashi et al. (120) | – | NSCLC | 23 | αGalCer/immature DC-enriched PBMC |
| Kunii et al. (121) | – | Head and neck SCC | 8 | αGalCer/immature DC-enriched PBMC + αGalCer/IL-2-expanded PBMC |
| Yamasaki et al. (122) | UMIN000000852 | Head and neck SCC | 10 | αGalCer-pulsed APCs + activated Vα24 NKT cell + surgery |
| Kurosaki et al. (123) | UMIN000001933 | Head and neck SCC | 17 | a-GalCer/immature DC-enriched PBMC |
| Nagato et al. (124) | NSCLC | 4 | αGalCer /immature DC-enriched PBMC | |
| Richter et al. (44) | NCT00698776 | Multiple myeloma | 6 | αGalCer /mature MoDC + lenalidomide |
| Exley et al. (125) | NCT00631072 | Advanced melanoma | 9 | Ex-vivo expanded iNKT cells |
| Gasser et al. (126) | Advanced melanoma | 8 | αGalCer + NY-ESO-1/mature MoDC | |
| Heczey et al. (127) | NCT03294954 | Neuroblastoma | 24 (R) | Autologous GD2-CAR NKT cells expressing IL-15 |
| – | NCT04754100 | Multiple myeloma | 30 (R) | agent-797 iNKT therapy |
| – | NCT03774654 | B cell malignancies | 48 (R) | Allogenic CD19-CAR NKT cells expressing IL-15 |
| – | NCT04751786 | Advanced Solid Tumor (NY-ESO-1+) | 15 (R) | iNKT cell activator PRECIOUS-01 + NY-ESO-1 encapsulated in nanoparticles |
| – | NCT04814004 | ALL, CLL, and B-cell lymphoma | 20 (R) | Autologous CD19-CAR iNKT cells expressing IL-15 |
Listed are the studies, the trial ID number when available, the tumor type, the number of patients involved and the type of treatment. NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; R, recruiting.